FDA
-
-
-
-
-
-
-
Zymeworks reports positive phase 1 data for cancer drug ZW191
-
-
-
-
-
-
-
Zymeworks Appoints Kristin Stafford as Chief Financial Officer
-
-
-
-
-
-
-
Zymeworks secures $250 million in royalty-backed financing from Royalty Pharma
-
-
-
-
-
-
-
Citizens Starts Zymeworks (ZYME) at Market Outperform
-
-
-
-
-
-
-
Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advan
-
-
-
-
-
-
-
Zymeworks to present ZW191 clinical data at cancer conference
-
-
-
-
-
-
-
Zymeworks adds two directors to board of directors
-
322,502 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

